Seeking Alpha

Rodman & Renshaw initiates coverage on Pharmacyclics (PCYC -0.1%) with a Market Perform rating...

Rodman & Renshaw initiates coverage on Pharmacyclics (PCYC -0.1%) with a Market Perform rating and $20 price target. Analysts with the firm see more upside for the clinical-stage biopharmaceutical company even with a 149% YTD run up in shares on the books.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs